Back

The rapid emergence of Salmonella Typhi with decreased ciprofloxacin susceptibility following an increase in ciprofloxacin prescriptions in Blantyre, Malawi

Ashton, P. M.; Chunga Chirambo, A.; Meiring, J. E.; Patel, P. D.; Mbewe, M.; Silungwe, N.; Chizani, K.; Banda, H.; Heyderman, R. S.; Dyson, Z. A.; MacPherson, P.; Henrion, M. Y. R.; STRATAA Study Group, ; Holt, K. E.; Gordon, M. A.

2023-03-29 infectious diseases
10.1101/2023.03.27.23287794 medRxiv
Show abstract

Ciprofloxacin is the first-line drug for treating typhoid fever in many high burden countries in Africa, but the emergence of non-susceptibility poses a grave challenge to public health programmes. Through enhanced surveillance as part of vaccine evaluation, we set out to investigate the occurrence and determinants of ciprofloxacin non-susceptibility in Blantyre, Malawi. We performed systematic typhoid fever and antibiotic prescription surveillance in two health centres in Blantyre, Malawi between 01/10/2016 and 31/10/2019, as part of the STRATAA and TyVAC studies. Blood culture isolates from study participants underwent i) pefloxacin screening and ciprofloxacin E-tests to identify ciprofloxcain non-susceptibility and ii) whole genome sequencing (WGS) to identify drug resistance mutations and phylogenetic relationships between non-susceptible and sensitive isolates. We constructed generalised linear regression models to investigate associations between ciprofloxacin prescription rates and S. Typhi isolates with Quinolone Resistance Determining Region (QRDR) mutations. We carried out 11295 blood cultures and microbiologically confirmed 239 cases of typhoid fever, with isolates from 193 participants sequenced (mean age of participants with sequenced genomes 12.8 years, 47% male). Between October 2016 and August 2019 2% (n=4/175) of WGS-confirmed typhoid fever cases were caused by S. Typhi with QRDR mutations, compared with 33% (n=6/18) in September and October 2019. Nine of the ten S. Typhi with QRDR mutations had a decreased ciprofloxacin susceptibility phenotype. Every additional prescription of ciprofloxacin given to study participants in the preceding month was associated with a 4.2% increase in the relative risk of isolating S. Typhi with a QRDR mutation (95% CI, 1.8-7.0%, p=0.0008). Phylogenetic analysis showed that S. Typhi isolates with QRDR mutations in September/October 2019 belonged to two distinct sub-clades encoding two different QRDR mutations, and were closely related (0-6 SNPs) to susceptible S. Typhi endemic to Blantyre. We have shown a close temporal association between empiric antimicrobial usage with an increase of fluoroquinolone non-susceptibility in S. Typhi, with two sub-clades responsible for the increase. Decreasing ciprofloxacin usage by improving typhoid diagnostics could help to limit the emergence of resistance.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
The Lancet Microbe
43 papers in training set
Top 0.1%
16.8%
2
Clinical Infectious Diseases
231 papers in training set
Top 0.4%
9.7%
3
Nature Communications
4913 papers in training set
Top 24%
8.0%
4
Microbial Genomics
204 papers in training set
Top 0.5%
4.6%
5
The Journal of Infectious Diseases
182 papers in training set
Top 0.7%
4.6%
6
The Lancet Infectious Diseases
71 papers in training set
Top 0.5%
4.6%
7
Open Forum Infectious Diseases
134 papers in training set
Top 0.5%
3.4%
50% of probability mass above
8
Emerging Infectious Diseases
103 papers in training set
Top 0.7%
3.4%
9
Nature Medicine
117 papers in training set
Top 1.0%
3.4%
10
Eurosurveillance
80 papers in training set
Top 0.4%
2.9%
11
Journal of Infection
71 papers in training set
Top 0.6%
2.9%
12
BMC Infectious Diseases
118 papers in training set
Top 2%
2.6%
13
Scientific Reports
3102 papers in training set
Top 52%
2.0%
14
Communications Medicine
85 papers in training set
Top 0.1%
2.0%
15
International Journal of Infectious Diseases
126 papers in training set
Top 1%
1.8%
16
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 1%
1.6%
17
JAC-Antimicrobial Resistance
13 papers in training set
Top 0.3%
1.4%
18
Journal of Clinical Microbiology
120 papers in training set
Top 1%
1.3%
19
PLOS Medicine
98 papers in training set
Top 3%
1.3%
20
Genome Medicine
154 papers in training set
Top 6%
1.3%
21
Journal of Antimicrobial Chemotherapy
43 papers in training set
Top 0.3%
1.2%
22
eBioMedicine
130 papers in training set
Top 2%
1.2%
23
New England Journal of Medicine
50 papers in training set
Top 0.7%
0.9%
24
Clinical Microbiology and Infection
60 papers in training set
Top 1%
0.9%
25
PLOS Neglected Tropical Diseases
378 papers in training set
Top 5%
0.9%
26
eLife
5422 papers in training set
Top 57%
0.8%
27
mBio
750 papers in training set
Top 12%
0.7%
28
EMBO Molecular Medicine
85 papers in training set
Top 6%
0.6%
29
The Lancet Global Health
24 papers in training set
Top 1%
0.6%